# To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV

> **NCT05854381** · PHASE1 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 93 (actual)

## Conditions studied

- HIV I Infection

## Interventions

- **BIOLOGICAL:** VIR-1388
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT05854381
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-09-19
- **Primary completion:** 2025-09-19
- **Final completion:** 2025-11-19
- **Target enrollment:** 93 (ACTUAL)
- **Last updated:** 2026-03-03

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05854381

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05854381, "To Investigate Safety, Reactogenicity and Immunogenicity of VIR-1388 Compared With Placebo in Participants Without HIV". Retrieved via AI Analytics 2026-07-25 from https://api.ai-analytics.org/clinical/NCT05854381. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*